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Abstract. PEPPER is a newly-launched three-year research project,
funded by the EU Horizon 2020 Framework. It will create a portable
personalised decision support system to empower individuals on in-
sulin therapy to self-manage their condition. PEPPER employs Case-
Based Reasoning to advise about insulin bolus doses, drawing on
various sources of physiological, lifestyle, environmental and social
data. It also uses a Model-Based Reasoning approach to maximise
users’ safety. The system will be integrated with an unobtrusive in-
sulin patch pump and has a patient-centric development approach in
order to improve patient self-efficacy and adherence to treatment.
1 INTRODUCTION
Type 1 diabetes (T1D) is a chronic disease caused by an autoim-
mune destruction of the pancreatic beta cells. This leaves the body
unable to produce the insulin needed to regulate blood glucose levels.
The condition is usually controlled through multiple daily injections
(MDI) of insulin to mimic the natural insulin secretion of a healthy
pancreas. Alternatively, some people are treated with continuous sub-
cutaneous insulin infusion (CSII) via a wearable pump. In both cases
the size of each insulin doses are chosen by the individual.
Decision support tools exist to support this process, such as in-
sulin bolus calculators that use simple mathematical formulae based
on metabolic parameters (i.e. insulin-to-carbohydrate ratio and in-
sulin sensitivity factor) and an estimation of the active insulin from
previous doses. Such tools are integrated into most insulin pumps
[9], and some glucose meters. There is also an increasing adoption
of decision support tools implemented on mobile devices [10], often
in conjunction with remote data storage in the cloud, though few are
approved by regulatory bodies such as the FDA. Some gather inputs
via wearable sensors (i.e. continuous glucose monitors), but most of
them rely on manual input. In practice, the latter are rarely used be-
cause most people with T1D find the process tedious and refuse to
interact with such systems [10, 2]. Hence a guiding design principle
for PEPPER is that wherever possible data is collected automatically,
via wearable technology. The information collected by the sensors
is managed by a Case-Based Reasoning (CBR) module to provide
personalised insulin recommendations, while a second Model-Based
Reasoning (MBR) module is used to maximise users’ safety.
2 SYSTEM OVERVIEW
The PEPPER system shown in Figure 1 offers insulin dosing advice
that is highly adaptive to the insulin needs of individuals by using
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a CBR approach. It also guarantees individuals’ safety by means of
a MBR approach that includes predictive glucose alarms, automatic
insulin suspension, carbohydrate recommendations and fault diag-
nosis. PEPPER offers a dual architecture to cater for both MDI or
CSII treatment, the latter via the unobtrusive Cellnovo patch-pump
(Cellnovo Ltd., UK). In both cases, the patient periodically wears
a continuous glucose monitor (CGM) used to automatically evalu-
ate glucose outcomes. An activity monitor, such the one integrated
in the Cellnovo pump or a commercially available one (e.g. Fitbit),
is included to determine physical activity automatically. Data from a
capillary blood glucose meter is periodically gathered to calibrate the
CGM or to be used in case CGM data is not available. Additional data
such as food intake, alcohol consumption, hormonal cycles are input
through the user interface of the handheld unit (smartphone or Cell-
novo handset). All inputs are then fed to the CBR engine on the hand-
held unit, and used to calculate the corresponding insulin dose. The
dose is then displayed for the user to accept or decline. If the recom-
mendation is accepted, the unit wirelessly sends the corresponding
command to the insulin pump, or the user manually injects the bolus
using an insulin pen. In addition, the safety module triggers alarms
to alert the user about predicted hypo- and hyperglycaemic events. In
the case of impending hypoglycaemia, the system also recommends
a personalised amount of carbohydrates to consume to eliminate hy-
poglycaemia and avoid rebound hyperglycaemia. It also suspends in-
sulin delivery for pump users when glucose levels are forecast to be
too low. If potentially dangerous events are not properly addressed by
the subject, automatic alarms can be sent via an SMS service to the
expert team and selected carers. When network connectivity is avail-
able, the handheld unit sends the recorded data to a remote secure
server. Data is presented in meaningful visualisations and analysed
periodically to find non-optimal glucose patterns.
2.1 Case-Based Reasoning for Insulin Dosing
Case-Based Reasoning (CBR) is a consolidated artificial intelligence
technique, extensively applied in medicine, that tries to solve newly
encountered problems by applying solutions learned from similar
problems encountered in the past. In CBR, past situations are stored
in cases, which represent knowledge related to the various aspects of
the situation. The CBR cycle consists of four steps: Retrieve the most
similar case or cases; Reuse the information in that case to solve the
problem; Revise the proposed solution; Retain the parts of this expe-
rience likely to be useful for future problem solving [1].
The first project to use CBR to recommend changes in insulin ther-
apy for T1D management was the T-IDDM project [3], where it was
integrated with rule-based reasoning and a probabilistic model of the
effects of insulin on blood glucose levels. More recently, the IDSDM
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Figure 1. PEPPER architecture.
project [11] used CBR as the primary reasoning modality in a deci-
sion support tool for patients on insulin pump therapy, and introduced
other factors into the calculations, such as life events that can influ-
ence blood glucose levels. However, both projects were intended for
use by clinicians as opposed to the individuals with diabetes.
In PEPPER, the CBR cycle is divided into two parts: the local and
remote. The local part runs on the handheld unit and the remote part
on a server. Both parts contain a case-base and periodically the local
case-base is synchronised with the remote case-base. The evaluation
step of the CBR cycle occurs on the server and requires aproval by
an expert clinician before a new case is incorporated to the case-
base. The CBR parameters include CGM and capillary glucose data,
physical activity, time, location, basal insulin, hormone cycle, stress,
alcohol, meal composition, and sleep. Most of these parameters are
automatically collected (or calculated) by the handset unit. Excep-
tions include alcohol consumption, meal composition and hormone
cycles, which need to be manually inputed. A prototype version of
the algorithm has already been implemented and successfully tested
in silico [8] and in subsequent pilot studies [12]. PEPPER builds on
this prototype and furthers improves it by including more parameters
and automatising their recording.
2.2 Model-Based Reasoning for Safety
Model-Based Reasoning (MBR) is defined as the interaction of ob-
servation and prediction [5]. On the one hand, there is the actual sys-
tem (e.g T1D subject) whose behaviour can be observed; on the other
hand, there is the model of the system from which predictions (e.g.
glucose levels) can be made. Assuming that the models are correct,
any discrepancy found between observations and predictions are de-
faults on the device (e.g. CGM or pump fault). MBR techniques have
been previously proposed in the context of diabetes technology to
constrain insulin delivery by an artificial pancreas [4], predict hy-
poglycaemic events [6] and detect CGM and insulin pump faults [7].
PEPPER leverages these techniques to build a system that guarantees
safety of the user at any time. In addition, it incorporates an adaptive
carbohydrate recommender system to prevent hypoglycaemic events.
3 CONCLUSION
The PEPPER system provides a portable personalised decision sup-
port system for insulin dosing that combines data from multiple
sources such as body-worn sensors and manual inputs. The Case-
Based Reasoning module is designed to provide a personalised in-
sulin dose which adapts over time. A Model-Based Reasoning mod-
ule is designed to maximise safety through prediction of adverse
events and the detection of faults. PEPPER is being developed using
a patient-centric approach in order to improve patient self-efficacy
and adherence to treatment. The software development will adhere
to international standards including those that apply to security and
interoperability. The final system will be tested in silico before be-
ing clinically validated over a 6-month non-randomised open-label
ambulatory trial.
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